TYRP1 and neoplasm: Meanwhile, a UCLA group showed that >90% of uveal melanoma tumors express TYRP1; optimized TYRP1-specific CAR-T cells were detected (even at low antigen density), halted the growth of patient-derived xenografts, and caused no off-tumor toxicity, clearing the way for a phase I trial [42].